{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:03:44Z","timestamp":1794632624796,"version":"4.9.1"},"reference-count":182,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Foundation of Tongji Hospital","award":["2023CXZH014 and 24-2KYC13057-08"],"award-info":[{"award-number":["2023CXZH014 and 24-2KYC13057-08"]}],"id":[{"id":"https:\/\/ror.org\/04xy45965","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Foundation of Tongji Hospital","award":["2023CXZH014 and 24-2KYC13057-08"],"award-info":[{"award-number":["2023CXZH014 and 24-2KYC13057-08"]}],"id":[{"id":"https:\/\/ror.org\/04xy45965","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203453"],"award-info":[{"award-number":["82203453"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2023YFC2705802"],"award-info":[{"award-number":["2023YFC2705802"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01722-1","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T08:31:22Z","timestamp":1751445082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistance"],"prefix":"10.1186","volume":"18","author":[{"given":"Xiaoxia","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canhui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juncheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"1722_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","volume":"22","author":"SU Khan","year":"2024","unstructured":"Khan SU, Fatima K, Aisha S, Malik F. Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal. 2024;22:109.","journal-title":"Cell Commun Signal"},{"key":"1722_CR2","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.7150\/ijbs.72534","volume":"18","author":"A Zhang","year":"2022","unstructured":"Zhang A, Miao K, Sun H, Deng CX. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int J Biol Sci. 2022;18:3019\u201333.","journal-title":"Int J Biol Sci"},{"key":"1722_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","volume":"9","author":"Y Xia","year":"2024","unstructured":"Xia Y, Sun M, Huang H, Jin WL. Drug repurposing for cancer therapy. Signal Transduct Target Ther. 2024;9:92.","journal-title":"Signal Transduct Target Ther"},{"key":"1722_CR4","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.21037\/atm-21-1948","volume":"9","author":"L Zhu","year":"2021","unstructured":"Zhu L, Jiang M, Wang H, Sun H, Zhu J, Zhao W, Fang Q, Yu J, Chen P, Wu S, Zheng Z, He Y. A narrative review of tumor heterogeneity and challenges to tumor drug therapy. Ann Transl Med. 2021;9:1351.","journal-title":"Ann Transl Med"},{"key":"1722_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.ccell.2021.07.009","volume":"39","author":"D Pe'er","year":"2021","unstructured":"Pe\u2019er D, Ogawa S, Elhanani O, Keren L, Oliver TG, Wedge D. Tumor heterogeneity. Cancer Cell. 2021;39:1015\u20137.","journal-title":"Cancer Cell"},{"key":"1722_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/1758834013517414","volume":"6","author":"F Janku","year":"2014","unstructured":"Janku F. Tumor heterogeneity in the clinic: is it a real problem? Ther Adv Med Oncol. 2014;6:43\u201351.","journal-title":"Ther Adv Med Oncol"},{"key":"1722_CR7","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/s41467-022-29358-6","volume":"13","author":"G Gambardella","year":"2022","unstructured":"Gambardella G, Viscido G, Tumaini B, Isacchi A, Bosotti R, di Bernardo D. A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug response. Nat Commun. 2022;13:1714.","journal-title":"Nat Commun"},{"key":"1722_CR8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","volume":"166","author":"F Iorio","year":"2016","unstructured":"Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Gon\u00e7alves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, van Dyk E, Chang H, de Silva H, Heyn H, Deng X, Egan RK, Liu Q, Mironenko T, Mitropoulos X, Richardson L, Wang J, Zhang T, Moran S, Sayols S, Soleimani M, Tamborero D, Lopez-Bigas N, Ross-Macdonald P, Esteller M, Gray NS, Haber DA, Stratton MR, Benes CH, Wessels LFA, Saez-Rodriguez J, McDermott U, Garnett MJ. A Landscape of Pharmacogenomic Interactions in Cancer. Cell. 2016;166:740\u201354.","journal-title":"Cell"},{"key":"1722_CR9","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/nbt.2877","volume":"32","author":"JC Costello","year":"2014","unstructured":"Costello JC, Heiser LM, Georgii E, G\u00f6nen M, Menden MP, Wang NJ, Bansal M, Ammad-ud-din M, Hintsanen P, Khan SA, Mpindi JP, Kallioniemi O, Honkela A, Aittokallio T, Wennerberg K, Collins JJ, Gallahan D, Singer D, Saez-Rodriguez J, Kaski S, Gray JW, Stolovitzky G. A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol. 2014;32:1202\u201312.","journal-title":"Nat Biotechnol"},{"key":"1722_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nchembio.1986","volume":"12","author":"MG Rees","year":"2016","unstructured":"Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, Javaid S, Coletti ME, Jones VL, Bodycombe NE, Soule CK, Alexander B, Li A, Montgomery P, Kotz JD, Hon CS, Munoz B, Liefeld T, Dan\u010d\u00edk V, Haber DA, Clish CB, Bittker JA, Palmer M, Wagner BK, Clemons PA, Shamji AF, Schreiber SL. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol. 2016;12:109\u201316.","journal-title":"Nat Chem Biol"},{"key":"1722_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216894","volume":"591","author":"M El-Tanani","year":"2024","unstructured":"El-Tanani M, Rabbani SA, Babiker R, Rangraze I, Kapre S, Palakurthi SS, Alnuqaydan AM, Aljabali AA, Rizzo M, El-Tanani Y, Tambuwala MM. Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies. Cancer Lett. 2024;591: 216894.","journal-title":"Cancer Lett"},{"key":"1722_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374\u2013403.","journal-title":"Cancer Cell"},{"key":"1722_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309\u201322.","journal-title":"Cancer Cell"},{"key":"1722_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, Zhang B, Meng Q, Yu X, Shi S. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20:131.","journal-title":"Mol Cancer"},{"key":"1722_CR15","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41419-023-06119-x","volume":"14","author":"J Fang","year":"2023","unstructured":"Fang J, Lu Y, Zheng J, Jiang X, Shen H, Shang X, Lu Y, Fu P. Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications. Cell Death Dis. 2023;14:586.","journal-title":"Cell Death Dis"},{"key":"1722_CR16","doi-asserted-by":"publisher","first-page":"6498","DOI":"10.1038\/s41467-022-34271-z","volume":"13","author":"J Liao","year":"2022","unstructured":"Liao J, Qian J, Fang Y, Chen Z, Zhuang X, Zhang N, Shao X, Hu Y, Yang P, Cheng J, Hu Y, Yu L, Yang H, Zhang J, Lu X, Shao L, Wu D, Gao Y, Chen H, Fan X. De novo analysis of bulk RNA-seq data at spatially resolved single-cell resolution. Nat Commun. 2022;13:6498.","journal-title":"Nat Commun"},{"key":"1722_CR17","doi-asserted-by":"crossref","unstructured":"A. Gavish, M. Tyler, A. C. Greenwald, R. Hoefflin, D. Simkin, R. Tschernichovsky, N. Galili Darnell, E. Somech, C. Barbolin, T. Antman, D. Kovarsky, T. Barrett, L. N. Gonzalez Castro, D. Halder, R. Chanoch-Myers, J. Laffy, M. Mints, A. Wider, R. Tal, A. Spitzer, T. Hara, M. Raitses-Gurevich, C. Stossel, T. Golan, A. Tirosh, M. L. Suv\u00e0, S. V. Puram, I. Tirosh, Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature 618, 598\u2013606 (2023).","DOI":"10.1038\/s41586-023-06130-4"},{"key":"1722_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-021-01105-2","volume":"14","author":"Y Lei","year":"2021","unstructured":"Lei Y, Tang R, Xu J, Wang W, Zhang B, Liu J, Yu X, Shi S. Applications of single-cell sequencing in cancer research: progress and perspectives. J Hematol Oncol. 2021;14:91.","journal-title":"J Hematol Oncol"},{"key":"1722_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nmeth.1315","volume":"6","author":"F Tang","year":"2009","unstructured":"Tang F, Barbacioru C, Wang Y, Nordman E, Lee C, Xu N, Wang X, Bodeau J, Tuch BB, Siddiqui A, Lao K, Surani MA. mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods. 2009;6:377\u201382.","journal-title":"Nat Methods"},{"key":"1722_CR20","doi-asserted-by":"crossref","unstructured":"Method of the year 2013. Nat Methods 11, 1 (2014).","DOI":"10.1038\/nmeth.2801"},{"key":"1722_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.694","volume":"12","author":"D Jovic","year":"2022","unstructured":"Jovic D, Liang X, Zeng H, Lin L, Xu F, Luo Y. Single-cell RNA sequencing technologies and applications: A brief overview. Clin Transl Med. 2022;12: e694.","journal-title":"Clin Transl Med"},{"key":"1722_CR22","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.cell.2015.10.039","volume":"163","author":"D Gr\u00fcn","year":"2015","unstructured":"Gr\u00fcn D, van Oudenaarden A. Design and Analysis of Single-Cell Sequencing Experiments. Cell. 2015;163:799\u2013810.","journal-title":"Cell"},{"key":"1722_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41422-023-00909-w","volume":"34","author":"LP Ge","year":"2024","unstructured":"Ge LP, Jin X, Ma D, Wang ZY, Liu CL, Zhou CZ, Zhao S, Yu TJ, Liu XY, Di GH, Shao ZM, Jiang YZ. ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer. Cell Res. 2024;34:58\u201375.","journal-title":"Cell Res"},{"key":"1722_CR24","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s43018-024-00824-y","volume":"5","author":"X Qiu","year":"2024","unstructured":"Qiu X, Zhou T, Li S, Wu J, Tang J, Ma G, Yang S, Hu J, Wang K, Shen S, Wang H, Chen L. Spatial single-cell protein landscape reveals vimentin(high) macrophages as immune-suppressive in the microenvironment of hepatocellular carcinoma. Nat Cancer. 2024;5:1557\u201378.","journal-title":"Nat Cancer"},{"key":"1722_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1146\/annurev-immunol-110519-071134","volume":"39","author":"X Ren","year":"2021","unstructured":"Ren X, Zhang L, Zhang Y, Li Z, Siemers N, Zhang Z. Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironment. Annu Rev Immunol. 2021;39:583\u2013609.","journal-title":"Annu Rev Immunol"},{"key":"1722_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ccell.2020.06.012","volume":"38","author":"ND Marjanovic","year":"2020","unstructured":"Marjanovic ND, Hofree M, Chan JE, Canner D, Wu K, Trakala M, Hartmann GG, Smith OC, Kim JY, Evans KV, Hudson A, Ashenberg O, Porter CBM, Bejnood A, Subramanian A, Pitter K, Yan Y, Delorey T, Phillips DR, Shah N, Chaudhary O, Tsankov A, Hollmann T, Rekhtman N, Massion PP, Poirier JT, Mazutis L, Li R, Lee JH, Amon A, Rudin CM, Jacks T, Regev A, Tammela T. Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Cancer Cell. 2020;38:229-246.e213.","journal-title":"Cancer Cell"},{"key":"1722_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.aan6828","volume":"358","author":"MJT Stubbington","year":"2017","unstructured":"Stubbington MJT, Rozenblatt-Rosen O, Regev A, Teichmann SA. Single-cell transcriptomics to explore the immune system in health and disease. Science. 2017;358:58\u201363.","journal-title":"Science"},{"key":"1722_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nri.2017.76","volume":"18","author":"E Papalexi","year":"2018","unstructured":"Papalexi E, Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immunol. 2018;18:35\u201345.","journal-title":"Nat Rev Immunol"},{"key":"1722_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104846","volume":"97","author":"S Lin","year":"2023","unstructured":"Lin S, Sun Y, Cao C, Zhu Z, Xu Y, Liu B, Hu B, Peng T, Zhi W, Xu M, Ding W, Ren F, Ma D, Li G, Wu P. Single-nucleus RNA sequencing reveals heterogenous microenvironments and specific drug response between cervical squamous cell carcinoma and adenocarcinoma. EBioMedicine. 2023;97: 104846.","journal-title":"EBioMedicine"},{"key":"1722_CR30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cell.2023.11.037","volume":"187","author":"J Pozniak","year":"2024","unstructured":"Pozniak J, Pedri D, Landeloos E, Van Herck Y, Antoranz A, Vanwynsberghe L, Nowosad A, Roda N, Makhzami S, Bervoets G, Maciel LF, Pulido-Vicu\u00f1a CA, Pollaris L, Seurinck R, Zhao F, Flem-Karlsen K, Damsky W, Chen L, Karagianni D, Cinque S, Kint S, Vandereyken K, Rombaut B, Voet T, Vernaillen F, Annaert W, Lambrechts D, Boecxstaens V, Saeys Y, van den Oord J, Bosisio F, Karras P, Shain AH, Bosenberg M, Leucci E, Paschen A, Rambow F, Bechter O, Marine JC. A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. Cell. 2024;187:166-183.e125.","journal-title":"Cell"},{"key":"1722_CR31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.radonc.2019.11.003","volume":"142","author":"BS Jang","year":"2020","unstructured":"Jang BS, Han W, Kim IA. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer. Radiother Oncol. 2020;142:202\u20139.","journal-title":"Radiother Oncol"},{"key":"1722_CR32","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","volume":"10","author":"Y Kieffer","year":"2020","unstructured":"Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, Lameiras S, Albergante L, Bonneau C, Guyard A, Tarte K, Zinovyev A, Baulande S, Zalcman G, Vincent-Salomon A, Mechta-Grigoriou F. Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer. Cancer Discov. 2020;10:1330\u201351.","journal-title":"Cancer Discov"},{"key":"1722_CR33","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41591-020-0926-0","volume":"26","author":"B Izar","year":"2020","unstructured":"Izar B, Tirosh I, Stover EH, Wakiro I, Cuoco MS, Alter I, Rodman C, Leeson R, Su MJ, Shah P, Iwanicki M, Walker SR, Kanodia A, Melms JC, Mei S, Lin JR, Porter CBM, Slyper M, Waldman J, Jerby-Arnon L, Ashenberg O, Brinker TJ, Mills C, Rogava M, Vigneau S, Sorger PK, Garraway LA, Konstantinopoulos PA, Liu JF, Matulonis U, Johnson BE, Rozenblatt-Rosen O, Rotem A, Regev A. A single-cell landscape of high-grade serous ovarian cancer. Nat Med. 2020;26:1271\u20139.","journal-title":"Nat Med"},{"key":"1722_CR34","doi-asserted-by":"crossref","unstructured":"O. de Dios, M. A. Ram\u00edrez-Gonz\u00e1lez, I. G\u00f3mez-Soria, B. Segura-Collar, J. Manosalva, D. Meg\u00edas, C. E. De Andrea, L. Fern\u00e1ndez-Rubio, A. Hern\u00e1ndez-La\u00edn, J. M. Sep\u00falveda-S\u00e1nchez, M. E. Rodriguez-Ruiz, \u00c1. P\u00e9rez-N\u00fa\u00f1ez, D. A. Wainwright, R. Gargini, P. S\u00e1nchez-G\u00f3mez, NKG2C\/KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma. J Immunother Cancer 12, (2024).","DOI":"10.1136\/jitc-2024-009210"},{"key":"1722_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, Fallahi-Sichani M, Dutton-Regester K, Lin JR, Cohen O, Shah P, Lu D, Genshaft AS, Hughes TK, Ziegler CG, Kazer SW, Gaillard A, Kolb KE, Villani AC, Johannessen CM, Andreev AY, Van Allen EM, Bertagnolli M, Sorger PK, Sullivan RJ, Flaherty KT, Frederick DT, Jan\u00e9-Valbuena J, Yoon CH, Rozenblatt-Rosen O, Shalek AK, Regev A, Garraway LA. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352:189\u201396.","journal-title":"Science"},{"key":"1722_CR36","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41422-020-00402-8","volume":"30","author":"S Jin","year":"2020","unstructured":"Jin S, Li R, Chen MY, Yu C, Tang LQ, Liu YM, Li JP, Liu YN, Luo YL, Zhao Y, Zhang Y, Xia TL, Liu SX, Liu Q, Wang GN, You R, Peng JY, Li J, Han F, Wang J, Chen QY, Zhang L, Mai HQ, Gewurz BE, Zhao B, Young LS, Zhong Q, Bai F, Zeng MS. Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma. Cell Res. 2020;30:950\u201365.","journal-title":"Cell Res"},{"key":"1722_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41576-022-00509-1","volume":"24","author":"S Preissl","year":"2023","unstructured":"Preissl S, Gaulton KJ, Ren B. Characterizing cis-regulatory elements using single-cell epigenomics. Nat Rev Genet. 2023;24:21\u201343.","journal-title":"Nat Rev Genet"},{"key":"1722_CR38","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nature14590","volume":"523","author":"JD Buenrostro","year":"2015","unstructured":"Buenrostro JD, Wu B, Litzenburger UM, Ruff D, Gonzales ML, Snyder MP, Chang HY, Greenleaf WJ. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature. 2015;523:486\u201390.","journal-title":"Nature"},{"key":"1722_CR39","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1038\/s41467-020-15956-9","volume":"11","author":"Y Su","year":"2020","unstructured":"Su Y, Ko ME, Cheng H, Zhu R, Xue M, Wang J, Lee JW, Frankiw L, Xu A, Wong S, Robert L, Takata K, Yuan D, Lu Y, Huang S, Ribas A, Levine R, Nolan GP, Wei W, Plevritis SK, Li G, Baltimore D, Heath JR. Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line. Nat Commun. 2020;11:2345.","journal-title":"Nat Commun"},{"key":"1722_CR40","doi-asserted-by":"crossref","unstructured":"L. Minnoye, G. K. Marinov, T. Krausgruber, L. Pan, A. P. Marand, S. Secchia, W. J. Greenleaf, E. E. M. Furlong, K. Zhao, R. J. Schmitz, C. Bock, S. Aerts, Chromatin accessibility profiling methods. Nat Rev Methods Primers 1, (2021).","DOI":"10.1038\/s43586-020-00008-9"},{"key":"1722_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41576-018-0089-8","volume":"20","author":"SL Klemm","year":"2019","unstructured":"Klemm SL, Shipony Z, Greenleaf WJ. Chromatin accessibility and the regulatory epigenome. Nat Rev Genet. 2019;20:207\u201320.","journal-title":"Nat Rev Genet"},{"key":"1722_CR42","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","volume":"39","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Chen H, Mo H, Hu X, Gao R, Zhao Y, Liu B, Niu L, Sun X, Yu X, Wang Y, Chang Q, Gong T, Guan X, Hu T, Qian T, Xu B, Ma F, Zhang Z, Liu Z. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021;39:1578-1593.e1578.","journal-title":"Cancer Cell"},{"key":"1722_CR43","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41592-023-01791-5","volume":"20","author":"HM Bennett","year":"2023","unstructured":"Bennett HM, Stephenson W, Rose CM, Darmanis S. Single-cell proteomics enabled by next-generation sequencing or mass spectrometry. Nat Methods. 2023;20:363\u201374.","journal-title":"Nat Methods"},{"key":"1722_CR44","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/978-1-4939-9773-2_19","volume":"2055","author":"D Liu","year":"2020","unstructured":"Liu D, Paczkowski P, Mackay S, Ng C, Zhou J. Single-Cell Multiplexed Proteomics on the IsoLight Resolves Cellular Functional Heterogeneity to Reveal Clinical Responses of Cancer Patients to Immunotherapies. Methods Mol Biol. 2020;2055:413\u201331.","journal-title":"Methods Mol Biol"},{"key":"1722_CR45","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41592-019-0540-6","volume":"16","author":"V Marx","year":"2019","unstructured":"Marx V. A dream of single-cell proteomics. Nat Methods. 2019;16:809\u201312.","journal-title":"Nat Methods"},{"key":"1722_CR46","doi-asserted-by":"publisher","first-page":"6889","DOI":"10.1007\/s00216-023-04759-8","volume":"415","author":"R Ahmad","year":"2023","unstructured":"Ahmad R, Budnik B. A review of the current state of single-cell proteomics and future perspective. Anal Bioanal Chem. 2023;415:6889\u201399.","journal-title":"Anal Bioanal Chem"},{"key":"1722_CR47","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41592-023-01828-9","volume":"20","author":"challenges and prospects","year":"2023","unstructured":"challenges and prospects. Single-cell proteomics. Nat Methods. 2023;20:317\u20138.","journal-title":"Nat Methods"},{"key":"1722_CR48","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41592-024-02243-4","volume":"21","author":"SE Irac","year":"2024","unstructured":"Irac SE, Soon MSF, Borcherding N, Tuong ZK. Single-cell immune repertoire analysis. Nat Methods. 2024;21:777\u201392.","journal-title":"Nat Methods"},{"key":"1722_CR49","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s41592-020-0867-z","volume":"18","author":"AV Joglekar","year":"2021","unstructured":"Joglekar AV, Li G. T cell antigen discovery. Nat Methods. 2021;18:873\u201380.","journal-title":"Nat Methods"},{"key":"1722_CR50","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s41467-022-29175-x","volume":"13","author":"S Gao","year":"2022","unstructured":"Gao S, Wu Z, Arnold B, Diamond C, Batchu S, Giudice V, Alemu L, Raffo DQ, Feng X, Kajigaya S, Barrett J, Ito S, Young NS. Single-cell RNA sequencing coupled to TCR profiling of large granular lymphocyte leukemia T cells. Nat Commun. 2022;13:1982.","journal-title":"Nat Commun"},{"key":"1722_CR51","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nmeth.3800","volume":"13","author":"MJT Stubbington","year":"2016","unstructured":"Stubbington MJT, L\u00f6nnberg T, Proserpio V, Clare S, Speak AO, Dougan G, Teichmann SA. T cell fate and clonality inference from single-cell transcriptomes. Nat Methods. 2016;13:329\u201332.","journal-title":"Nat Methods"},{"key":"1722_CR52","doi-asserted-by":"crossref","unstructured":"F. Horns, C. Vollmers, D. Croote, S. F. Mackey, G. E. Swan, C. L. Dekker, M. M. Davis, S. R. Quake, Lineage tracing of human B cells reveals the in vivo landscape of human antibody class switching. Elife 5, (2016).","DOI":"10.7554\/eLife.16578"},{"key":"1722_CR53","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","volume":"564","author":"L Zhang","year":"2018","unstructured":"Zhang L, Yu X, Zheng L, Zhang Y, Li Y, Fang Q, Gao R, Kang B, Zhang Q, Huang JY, Konno H, Guo X, Ye Y, Gao S, Wang S, Hu X, Ren X, Shen Z, Ouyang W, Zhang Z. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature. 2018;564:268\u201372.","journal-title":"Nature"},{"key":"1722_CR54","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/ng.3822","volume":"49","author":"RO Emerson","year":"2017","unstructured":"Emerson RO, DeWitt WS, Vignali M, Gravley J, Hu JK, Osborne EJ, Desmarais C, Klinger M, Carlson CS, Hansen JA, Rieder M, Robins HS. Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire. Nat Genet. 2017;49:659\u201365.","journal-title":"Nat Genet"},{"key":"1722_CR55","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-021-03634-9","volume":"596","author":"A Rao","year":"2021","unstructured":"Rao A, Barkley D, Fran\u00e7a GS, Yanai I. Exploring tissue architecture using spatial transcriptomics. Nature. 2021;596:211\u201320.","journal-title":"Nature"},{"key":"1722_CR56","doi-asserted-by":"crossref","unstructured":"Method of the Year 2020: spatially resolved transcriptomics. Nat Methods 18, 1 (2021).","DOI":"10.1038\/s41592-020-01042-x"},{"key":"1722_CR57","doi-asserted-by":"crossref","unstructured":"Y. Si, J. S. Lee, G. Jun, H. M. Kang, J. H. Lee, Spatial omics enters the microscopic realm: opportunities and challenges. Trends Genet, (2025).","DOI":"10.1016\/j.tig.2025.05.002"},{"key":"1722_CR58","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41586-019-1049-y","volume":"568","author":"CL Eng","year":"2019","unstructured":"Eng CL, Lawson M, Zhu Q, Dries R, Koulena N, Takei Y, Yun J, Cronin C, Karp C, Yuan GC, Cai L. Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH. Nature. 2019;568:235\u20139.","journal-title":"Nature"},{"key":"1722_CR59","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaw1219","volume":"363","author":"SG Rodriques","year":"2019","unstructured":"Rodriques SG, Stickels RR, Goeva A, Martin CA, Murray E, Vanderburg CR, Welch J, Chen LM, Chen F, Macosko EZ. Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution. Science. 2019;363:1463\u20137.","journal-title":"Science"},{"key":"1722_CR60","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41576-019-0129-z","volume":"20","author":"DJ Burgess","year":"2019","unstructured":"Burgess DJ. Spatial transcriptomics coming of age. Nat Rev Genet. 2019;20:317.","journal-title":"Nat Rev Genet"},{"key":"1722_CR61","doi-asserted-by":"crossref","unstructured":"R. L. Castillo, I. Sidhu, I. Dolgalev, T. Chu, A. Prystupa, I. Subudhi, D. Yan, P. Konieczny, B. Hsieh, R. H. Haberman, S. Selvaraj, T. Shiomi, R. Medina, P. V. Girija, A. Heguy, C. A. Loomis, L. Chiriboga, C. Ritchlin, M. L. Garcia-Hernandez, J. Carucci, S. A. Meehan, A. L. Neimann, J. E. Gudjonsson, J. U. Scher, S. Naik, Spatial transcriptomics stratifies psoriatic disease severity by emergent cellular ecosystems. Sci Immunol 8, eabq7991 (2023).","DOI":"10.1126\/sciimmunol.abq7991"},{"key":"1722_CR62","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s41593-023-01379-4","volume":"26","author":"J Wu","year":"2023","unstructured":"Wu J, Li Y, Huang Y, Liu L, Zhang H, Nagy C, Tan X, Cheng K, Liu Y, Pu J, Wang H, Wu Q, Perry SW, Turecki G, Wong ML, Licinio J, Zheng P, Xie P. Integrating spatial and single-nucleus transcriptomic data elucidates microglial-specific responses in female cynomolgus macaques with depressive-like behaviors. Nat Neurosci. 2023;26:1352\u201364.","journal-title":"Nat Neurosci"},{"key":"1722_CR63","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41421-023-00621-4","volume":"9","author":"F Wu","year":"2023","unstructured":"Wu F, Zhang X, Wang M, Zhang J, Chen M, Ren Z, Wu M, Song P, Yu J, Chen D. Deciphering the role of immunoglobulin secreting malignant lineages in the invasive frontiers of small cell lung cancer by scRNA-seq and spatial transcriptomics analysis. Cell Discov. 2023;9:123.","journal-title":"Cell Discov"},{"key":"1722_CR64","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41421-023-00591-7","volume":"9","author":"Y Wang","year":"2023","unstructured":"Wang Y, Liu B, Min Q, Yang X, Yan S, Ma Y, Li S, Fan J, Wang Y, Dong B, Teng H, Lin D, Zhan Q, Wu N. Spatial transcriptomics delineates molecular features and cellular plasticity in lung adenocarcinoma progression. Cell Discov. 2023;9:96.","journal-title":"Cell Discov"},{"key":"1722_CR65","doi-asserted-by":"crossref","unstructured":"A. Franken, M. Bila, A. Mechels, S. Kint, J. Van Dessel, V. Pomella, S. Vanuytven, G. Philips, O. Bricard, J. Xiong, B. Boeckx, S. Hatse, T. Van Brussel, R. Schepers, C. Van Aerde, S. Geurs, V. Vandecaveye, E. Hauben, V. Vander Poorten, S. Verbandt, K. Vandereyken, J. Qian, S. Tejpar, T. Voet, P. M. Clement, D. Lambrechts, CD4(+) T\u00a0cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy. Immunity 57, 541\u2013558.e547 (2024).","DOI":"10.1016\/j.immuni.2024.02.007"},{"key":"1722_CR66","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41580-018-0094-y","volume":"20","author":"E Lundberg","year":"2019","unstructured":"Lundberg E, Borner GHH. Spatial proteomics: a powerful discovery tool for cell biology. Nat Rev Mol Cell Biol. 2019;20:285\u2013302.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1722_CR67","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41587-019-0207-y","volume":"37","author":"SK Saka","year":"2019","unstructured":"Saka SK, Wang Y, Kishi JY, Zhu A, Zeng Y, Xie W, Kirli K, Yapp C, Cicconet M, Beliveau BJ, Lapan SW, Yin S, Lin M, Boyden ES, Kaeser PS, Pihan G, Church GM, Yin P. Immuno-SABER enables highly multiplexed and amplified protein imaging in tissues. Nat Biotechnol. 2019;37:1080\u201390.","journal-title":"Nat Biotechnol"},{"key":"1722_CR68","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12953-024-00231-2","volume":"22","author":"M Wu","year":"2024","unstructured":"Wu M, Tao H, Xu T, Zheng X, Wen C, Wang G, Peng Y, Dai Y. Spatial proteomics: unveiling the multidimensional landscape of protein localization in human diseases. Proteome Sci. 2024;22:7.","journal-title":"Proteome Sci"},{"key":"1722_CR69","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1038\/s41596-021-00556-8","volume":"16","author":"S Black","year":"2021","unstructured":"Black S, Phillips D, Hickey JW, Kennedy-Darling J, Venkataraaman VG, Samusik N, Goltsev Y, Sch\u00fcrch CM, Nolan GP. CODEX multiplexed tissue imaging with DNA-conjugated antibodies. Nat Protoc. 2021;16:3802\u201335.","journal-title":"Nat Protoc"},{"key":"1722_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/biot.202100041","volume":"16","author":"N Wang","year":"2021","unstructured":"Wang N, Li X, Wang R, Ding Z. Spatial transcriptomics and proteomics technologies for deconvoluting the tumor microenvironment. Biotechnol J. 2021;16: e2100041.","journal-title":"Biotechnol J"},{"key":"1722_CR71","doi-asserted-by":"publisher","first-page":"6726","DOI":"10.1038\/s41467-021-26974-6","volume":"12","author":"D Phillips","year":"2021","unstructured":"Phillips D, Matusiak M, Gutierrez BR, Bhate SS, Barlow GL, Jiang S, Demeter J, Smythe KS, Pierce RH, Fling SP, Ramchurren N, Cheever MA, Goltsev Y, West RB, Khodadoust MS, Kim YH, Sch\u00fcrch CM, Nolan GP. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. Nat Commun. 2021;12:6726.","journal-title":"Nat Commun"},{"key":"1722_CR72","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke L, Brunet M, Gu\u00e9gan JP, Rey C, Bougouin A, Cousin S, Moulec SL, Besse B, Loriot Y, Larroquette M, Soubeyran I, Toulmonde M, Roubaud G, Pernot S, Cabart M, Chomy F, Lefevre C, Bourcier K, Kind M, Giglioli I, Saut\u00e8s-Fridman C, Velasco V, Courgeon F, Oflazoglu E, Savina A, Marabelle A, Soria JC, Bellera C, Sofeu C, Bessede A, Fridman WH, Loarer FL, Italiano A. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2021;2:794\u2013802.","journal-title":"Nat Cancer"},{"key":"1722_CR73","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/s42255-023-00881-0","volume":"5","author":"T Alexandrov","year":"2023","unstructured":"Alexandrov T. Spatial metabolomics: from a niche field towards a driver of innovation. Nat Metab. 2023;5:1443\u20135.","journal-title":"Nat Metab"},{"key":"1722_CR74","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41571-024-00926-7","volume":"21","author":"J Chen","year":"2024","unstructured":"Chen J, Larsson L, Swarbrick A, Lundeberg J. Spatial landscapes of cancers: insights and opportunities. Nat Rev Clin Oncol. 2024;21:660\u201374.","journal-title":"Nat Rev Clin Oncol"},{"key":"1722_CR75","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev-biodatasci-011420-031537","volume":"3","author":"T Alexandrov","year":"2020","unstructured":"Alexandrov T. Spatial Metabolomics and Imaging Mass Spectrometry in the Age of Artificial Intelligence. Annu Rev Biomed Data Sci. 2020;3:61\u201387.","journal-title":"Annu Rev Biomed Data Sci"},{"key":"1722_CR76","doi-asserted-by":"crossref","unstructured":"D. R. Schmidt, R. Patel, D. G. Kirsch, C. A. Lewis, M. G. Vander Heiden, J. W. Locasale, Metabolomics in cancer research and emerging applications in clinical oncology. CA Cancer J Clin 71, 333\u2013358 (2021).","DOI":"10.3322\/caac.21670"},{"key":"1722_CR77","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1038\/s41467-023-38360-5","volume":"14","author":"C Sun","year":"2023","unstructured":"Sun C, Wang A, Zhou Y, Chen P, Wang X, Huang J, Gao J, Wang X, Shu L, Lu J, Dai W, Bu Z, Ji J, He J. Spatially resolved multi-omics highlights cell-specific metabolic remodeling and interactions in gastric cancer. Nat Commun. 2023;14:2692.","journal-title":"Nat Commun"},{"key":"1722_CR78","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3rd, Hao Y, Stoeckius M, Smibert P, Satija R. Comprehensive Integration of Single-Cell Data. Cell. 2019;177:1888-1902.e1821.","journal-title":"Cell"},{"key":"1722_CR79","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41580-023-00615-w","volume":"24","author":"A Baysoy","year":"2023","unstructured":"Baysoy A, Bai Z, Satija R, Fan R. The technological landscape and applications of single-cell multi-omics. Nat Rev Mol Cell Biol. 2023;24:695\u2013713.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1722_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.03.063","volume":"31","author":"F Mair","year":"2020","unstructured":"Mair F, Erickson JR, Voillet V, Simoni Y, Bi T, Tyznik AJ, Martin J, Gottardo R, Newell EW, Prlic M. A Targeted Multi-omic Analysis Approach Measures Protein Expression and Low-Abundance Transcripts on the Single-Cell Level. Cell Rep. 2020;31: 107499.","journal-title":"Cell Rep"},{"key":"1722_CR81","doi-asserted-by":"crossref","unstructured":"A. Bassez, H. Vos, L. Van Dyck, G. Floris, I. Arijs, C. Desmedt, B. Boeckx, M. Vanden Bempt, I. Nevelsteen, K. Lambein, K. Punie, P. Neven, A. D. Garg, H. Wildiers, J. Qian, A. Smeets, D. Lambrechts, A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat Med 27, 820\u2013832 (2021).","DOI":"10.1038\/s41591-021-01323-8"},{"key":"1722_CR82","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s43018-019-0022-x","volume":"1","author":"S Valpione","year":"2020","unstructured":"Valpione S, Galvani E, Tweedy J, Mundra PA, Banyard A, Middlehurst P, Barry J, Mills S, Salih Z, Weightman J, Gupta A, Gremel G, Baenke F, Dhomen N, Lorigan PC, Marais R. Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. Nat Cancer. 2020;1:210\u201321.","journal-title":"Nat Cancer"},{"key":"1722_CR83","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1200\/OP.20.00793","volume":"17","author":"EJ Cathcart-Rake","year":"2021","unstructured":"Cathcart-Rake EJ, Ruddy KJ, Bleyer A, Johnson RH. Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years. JCO Oncol Pract. 2021;17:305\u201313.","journal-title":"JCO Oncol Pract"},{"key":"1722_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108253","volume":"237","author":"JY So","year":"2022","unstructured":"So JY, Ohm J, Lipkowitz S, Yang L. Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options. Pharmacol Ther. 2022;237: 108253.","journal-title":"Pharmacol Ther"},{"key":"1722_CR85","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1200\/JCO.22.02403","volume":"41","author":"P McLaughlin","year":"2023","unstructured":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program. J Clin Oncol. 2023;41:154\u201362.","journal-title":"J Clin Oncol"},{"key":"1722_CR86","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","volume":"17","author":"ME Goebeler","year":"2020","unstructured":"Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol. 2020;17:418\u201334.","journal-title":"Nat Rev Clin Oncol"},{"key":"1722_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101159","volume":"77","author":"SH Lee","year":"2024","unstructured":"Lee SH, Kim S, Lee J, Kim Y, Joo Y, Heo JY, Lee H, Lee C, Hwang GS, Park H. Comprehensive metabolomic analysis identifies key biomarkers and modulators of immunotherapy response in NSCLC patients. Drug Resist Updat. 2024;77: 101159.","journal-title":"Drug Resist Updat"},{"key":"1722_CR88","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29\u201339.","journal-title":"Int Immunopharmacol"},{"key":"1722_CR89","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1084\/jem.20140692","volume":"211","author":"D \u00d6hlund","year":"2014","unstructured":"\u00d6hlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014;211:1503\u201323.","journal-title":"J Exp Med"},{"key":"1722_CR90","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00048.2019","volume":"101","author":"G Biffi","year":"2021","unstructured":"Biffi G, Tuveson DA. Diversity and Biology of Cancer-Associated Fibroblasts. Physiol Rev. 2021;101:147\u201376.","journal-title":"Physiol Rev"},{"key":"1722_CR91","doi-asserted-by":"crossref","unstructured":"Y. Gao, X. Li, C. Zeng, C. Liu, Q. Hao, W. Li, K. Zhang, W. Zhang, S. Wang, H. Zhao, D. Fan, M. Li, Y. Zhang, W. Zhang, C. Zhang, CD63(+) Cancer-Associated Fibroblasts Confer Tamoxifen Resistance to Breast Cancer Cells through Exosomal miR-22. Adv Sci (Weinh) 7, 2002518 (2020).","DOI":"10.1002\/advs.202002518"},{"key":"1722_CR92","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, Sirven P, Magagna I, Fuhrmann L, Bernard C, Bonneau C, Kondratova M, Kuperstein I, Zinovyev A, Givel AM, Parrini MC, Soumelis V, Vincent-Salomon A, Mechta-Grigoriou F. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. Cancer Cell. 2018;33:463-479.e410.","journal-title":"Cancer Cell"},{"key":"1722_CR93","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1038\/s41467-021-24343-x","volume":"12","author":"S Valpione","year":"2021","unstructured":"Valpione S, Mundra PA, Galvani E, Campana LG, Lorigan P, De Rosa F, Gupta A, Weightman J, Mills S, Dhomen N, Marais R. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. Nat Commun. 2021;12:4098.","journal-title":"Nat Commun"},{"key":"1722_CR94","doi-asserted-by":"crossref","unstructured":"J. Wagner, M. A. Rapsomaniki, S. Chevrier, T. Anzeneder, C. Langwieder, A. Dykgers, M. Rees, A. Ramaswamy, S. Muenst, S. D. Soysal, A. Jacobs, J. Windhager, K. Silina, M. van den Broek, K. J. Dedes, M. Rodr\u00edguez Mart\u00ednez, W. P. Weber, B. Bodenmiller, A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell 177, 1330\u20131345.e1318 (2019).","DOI":"10.1016\/j.cell.2019.03.005"},{"key":"1722_CR95","unstructured":"Y. S. Nan Wang, Weifeng Hong, Hongnan Mo, Zhentao Song, Wenshuang Dai, Lianshui Wang, Haiyang Zhang, Yuyan Zhang, Qi Zhang, Hui Zhang, Tao Zhang, Yuyi Wang, Yeyu Li, Jiafei Ma, Changchao Shao, Min Yu, Haili Qian, Fei Ma, Zhiyong Ding, Spatial Single-Cell Transcriptomic Analysis in Breast Cancer Reveals Potential Biomarkers for PD1 Blockade Therapy. Research Square, (2024)."},{"key":"1722_CR96","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cell.2020.02.015","volume":"180","author":"Y Lu","year":"2020","unstructured":"Lu Y, Zhao Q, Liao JY, Song E, Xia Q, Pan J, Li Y, Li J, Zhou B, Ye Y, Di C, Yu S, Zeng Y, Su S. Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity. Cell. 2020;180:1081-1097.e1024.","journal-title":"Cell"},{"key":"1722_CR97","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12935-024-03220-9","volume":"24","author":"MY Hsieh","year":"2024","unstructured":"Hsieh MY, Hsu SK, Liu TY, Wu CY, Chiu CC. Melanoma biology and treatment: a review of novel regulated cell death-based approaches. Cancer Cell Int. 2024;24:63.","journal-title":"Cancer Cell Int"},{"key":"1722_CR98","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","volume":"23","author":"AC Huang","year":"2022","unstructured":"Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23:660\u201370.","journal-title":"Nat Immunol"},{"key":"1722_CR99","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","volume":"6","author":"W Guo","year":"2021","unstructured":"Guo W, Wang H, Li C. Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther. 2021;6:424.","journal-title":"Signal Transduct Target Ther"},{"key":"1722_CR100","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cell.2018.12.034","volume":"176","author":"M Sade-Feldman","year":"2019","unstructured":"Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2019;176:404.","journal-title":"Cell"},{"key":"1722_CR101","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568\u201371.","journal-title":"Nature"},{"key":"1722_CR102","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41591-019-0734-6","volume":"26","author":"BP Fairfax","year":"2020","unstructured":"Fairfax BP, Taylor CA, Watson RA, Nassiri I, Danielli S, Fang H, Mah\u00e9 EA, Cooper R, Woodcock V, Traill Z, Al-Mossawi MH, Knight JC, Klenerman P, Payne M, Middleton MR. Peripheral CD8(+) T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma. Nat Med. 2020;26:193\u20139.","journal-title":"Nat Med"},{"key":"1722_CR103","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1200\/JCO.21.00675","volume":"39","author":"A Diab","year":"2021","unstructured":"Diab A, Tykodi SS, Daniels GA, Maio M, Curti BD, Lewis KD, Jang S, Kalinka E, Puzanov I, Spira AI, Cho DC, Guan S, Puente E, Nguyen T, Hoch U, Currie SL, Lin W, Tagliaferri MA, Zalevsky J, Sznol M, Hurwitz ME. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. J Clin Oncol. 2021;39:2914\u201325.","journal-title":"J Clin Oncol"},{"key":"1722_CR104","doi-asserted-by":"crossref","unstructured":"C. F. Friedman, C. Spencer, C. R. Cabanski, K. S. Panageas, D. K. Wells, A. Ribas, H. Tawbi, K. Tsai, M. Postow, A. Shoushtari, P. Chapman, J. Karakunnel, S. Bucktrout, P. Gherardini, T. J. Hollmann, R. O. Chen, M. Callahan, T. LaVallee, R. Ibrahim, J. Wolchok, Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. J Immunother Cancer 10, (2022).","DOI":"10.1136\/jitc-2021-003853"},{"key":"1722_CR105","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, Ca\u00f1adas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018;175:984-997.e924.","journal-title":"Cell"},{"key":"1722_CR106","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1722_CR107","doi-asserted-by":"publisher","first-page":"7802","DOI":"10.1038\/s41467-023-43282-3","volume":"14","author":"TT Gong","year":"2023","unstructured":"Gong TT, Guo S, Liu FH, Huo YL, Zhang M, Yan S, Zhou HX, Pan X, Wang XY, Xu HL, Kang Y, Li YZ, Qin X, Xiao Q, Huang DH, Li XY, Zhao YY, Zhao XX, Wang YL, Ma XX, Gao S, Zhao YH, Ning SW, Wu QJ. Proteomic characterization of epithelial ovarian cancer delineates molecular signatures and therapeutic targets in distinct histological subtypes. Nat Commun. 2023;14:7802.","journal-title":"Nat Commun"},{"key":"1722_CR108","doi-asserted-by":"crossref","unstructured":"R. J. Kurman, M. Shih Ie, The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34, 433\u2013443 (2010).","DOI":"10.1097\/PAS.0b013e3181cf3d79"},{"issue":"Suppl 10","key":"1722_CR109","doi-asserted-by":"publisher","first-page":"x118","DOI":"10.1093\/annonc\/mds315","volume":"23","author":"FA Raja","year":"2012","unstructured":"Raja FA, Chopra N, Ledermann JA. Optimal first-line treatment in ovarian cancer. Ann Oncol. 2012;23(Suppl 10):x118-127.","journal-title":"Ann Oncol"},{"key":"1722_CR110","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41388-021-02139-z","volume":"41","author":"T Kan","year":"2022","unstructured":"Kan T, Zhang S, Zhou S, Zhang Y, Zhao Y, Gao Y, Zhang T, Gao F, Wang X, Zhao L, Yang M. Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence. Oncogene. 2022;41:895\u2013906.","journal-title":"Oncogene"},{"key":"1722_CR111","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/carcin\/bgae013","volume":"45","author":"H Kim","year":"2024","unstructured":"Kim H, Son S, Ko Y, Lim H, Lee J, Lee KM, Shin I. CYR61 confers chemoresistance by upregulating survivin expression in triple-negative breast cancer. Carcinogenesis. 2024;45:510\u20139.","journal-title":"Carcinogenesis"},{"key":"1722_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101532","volume":"5","author":"Y Mori","year":"2024","unstructured":"Mori Y, Okimoto Y, Sakai H, Kanda Y, Ohata H, Shiokawa D, Suzuki M, Yoshida H, Ueda H, Sekizuka T, Tamura R, Yamawaki K, Ishiguro T, Mateos RN, Shiraishi Y, Yatabe Y, Hamada A, Yoshihara K, Enomoto T, Okamoto K. Targeting PDGF signaling of cancer-associated fibroblasts blocks feedback activation of HIF-1\u03b1 and tumor progression of clear cell ovarian cancer. Cell Rep Med. 2024;5: 101532.","journal-title":"Cell Rep Med"},{"key":"1722_CR113","doi-asserted-by":"crossref","unstructured":"M. Olislagers, F. C. de Jong, V. C. Rutten, J. L. Boormans, T. Mahmoudi, T. C. M. Zuiverloon, Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification. Nat Rev Urol, (2024).","DOI":"10.1038\/s41585-024-00914-7"},{"key":"1722_CR114","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41585-022-00693-z","volume":"20","author":"E Grobet-Jeandin","year":"2023","unstructured":"Grobet-Jeandin E, Pinar U, Parra J, Roupr\u00eat M, Seisen T. Health-related quality of life after curative treatment for muscle-invasive bladder cancer. Nat Rev Urol. 2023;20:279\u201393.","journal-title":"Nat Rev Urol"},{"key":"1722_CR115","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1200\/EDBK_240837","volume":"39","author":"CM Fares","year":"2019","unstructured":"Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? Am Soc Clin Oncol Educ Book. 2019;39:147\u201364.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1722_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","volume":"11","author":"Y Pan","year":"2020","unstructured":"Pan Y, Yu Y, Wang X, Zhang T. Tumor-Associated Macrophages in Tumor Immunity. Front Immunol. 2020;11: 583084.","journal-title":"Front Immunol"},{"key":"1722_CR117","doi-asserted-by":"crossref","unstructured":"Y. Xu, H. Zeng, K. Jin, Z. Liu, Y. Zhu, L. Xu, Z. Wang, Y. Chang, J. Xu, Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. J Immunother Cancer 10, (2022).","DOI":"10.1136\/jitc-2021-003416"},{"key":"1722_CR118","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","volume":"181","author":"DY Oh","year":"2020","unstructured":"Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. Intratumoral CD4(+) T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell. 2020;181:1612-1625.e1613.","journal-title":"Cell"},{"key":"1722_CR119","unstructured":"A. Brown, S. Kumar, P. B. Tchounwou, Cisplatin-Based Chemotherapy of Human Cancers. J Cancer Sci Ther 11, (2019)."},{"key":"1722_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101059","volume":"73","author":"F Li","year":"2024","unstructured":"Li F, Zhang H, Huang Y, Li D, Zheng Z, Xie K, Cao C, Wang Q, Zhao X, Huang Z, Chen S, Chen H, Fan Q, Deng F, Hou L, Deng X, Tan W. Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer. Drug Resist Updat. 2024;73: 101059.","journal-title":"Drug Resist Updat"},{"key":"1722_CR121","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.molmed.2019.04.012","volume":"25","author":"V Relli","year":"2019","unstructured":"Relli V, Trerotola M, Guerra E, Alberti S. Abandoning the Notion of Non-Small Cell Lung Cancer. Trends Mol Med. 2019;25:585\u201394.","journal-title":"Trends Mol Med"},{"key":"1722_CR122","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.semcancer.2022.05.004","volume":"86","author":"JJ Meijer","year":"2022","unstructured":"Meijer JJ, Leonetti A, Air\u00f2 G, Tiseo M, Rolfo C, Giovannetti E, Vahabi M. Small cell lung cancer: Novel treatments beyond immunotherapy. Semin Cancer Biol. 2022;86:376\u201385.","journal-title":"Semin Cancer Biol"},{"key":"1722_CR123","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1634\/theoncologist.2017-0078","volume":"22","author":"L Pai-Scherf","year":"2017","unstructured":"Pai-Scherf L, Blumenthal GM, Li H, Subramaniam S, Mishra-Kalyani PS, He K, Zhao H, Yu J, Paciga M, Goldberg KB, McKee AE, Keegan P, Pazdur R. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist. 2017;22:1392\u20139.","journal-title":"Oncologist"},{"key":"1722_CR124","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1002\/cam4.4191","volume":"10","author":"MM Teng","year":"2021","unstructured":"Teng MM, Chen SY, Yang B, Wang Y, Han RY, An MN, Dong YL, You HS. Determining the optimal PD-1\/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China. Cancer Med. 2021;10:6344\u201353.","journal-title":"Cancer Med"},{"key":"1722_CR125","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s00262-021-02848-0","volume":"70","author":"R Zhong","year":"2021","unstructured":"Zhong R, Zhang Y, Chen D, Cao S, Han B, Zhong H. Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient. Cancer Immunol Immunother. 2021;70:2261\u201374.","journal-title":"Cancer Immunol Immunother"},{"key":"1722_CR126","doi-asserted-by":"crossref","unstructured":"B. L. Horton, D. M. Morgan, N. Momin, M. Zagorulya, E. Torres-Mejia, V. Bhandarkar, K. D. Wittrup, J. C. Love, S. Spranger, Lack of CD8(+) T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. Sci Immunol 6, eabi8800 (2021).","DOI":"10.1126\/sciimmunol.abi8800"},{"key":"1722_CR127","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41588-024-01998-y","volume":"57","author":"Y Yan","year":"2025","unstructured":"Yan Y, Sun D, Hu J, Chen Y, Sun L, Yu H, Xiong Y, Huang Z, Xia H, Zhu X, Bian D, Sun F, Hou L, Wu C, Fan OR, Hu H, Zeng A, Zhang L, Sun YE, Wang C, Zhang P. Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer. Nat Genet. 2025;57:126\u201339.","journal-title":"Nat Genet"},{"key":"1722_CR128","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s42003-022-03402-z","volume":"5","author":"B Breznik","year":"2022","unstructured":"Breznik B, Ko MW, Tse C, Chen PC, Senjor E, Majc B, Habi\u010d A, Angelillis N, Novak M, \u017dupunski V, Mlakar J, Nathanson D, Jewett A. Infiltrating natural killer cells bind, lyse and increase chemotherapy efficacy in glioblastoma stem-like tumorospheres. Commun Biol. 2022;5:436.","journal-title":"Commun Biol"},{"key":"1722_CR129","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/labinvest.2017.19","volume":"97","author":"A Gieryng","year":"2017","unstructured":"Gieryng A, Pszczolkowska D, Walentynowicz KA, Rajan WD, Kaminska B. Immune microenvironment of gliomas. Lab Invest. 2017;97:498\u2013518.","journal-title":"Lab Invest"},{"key":"1722_CR130","first-page":"451","volume":"21","author":"X Kong","year":"2024","unstructured":"Kong X, Zhang J, Chen S, Wang X, Xi Q, Shen H, Zhang R. Immune checkpoint inhibitors: breakthroughs in cancer treatment. Cancer Biol Med. 2024;21:451\u201372.","journal-title":"Cancer Biol Med"},{"key":"1722_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101621","volume":"5","author":"H Yamaguchi","year":"2024","unstructured":"Yamaguchi H, Hsu JM, Sun L, Wang SC, Hung MC. Advances and prospects of biomarkers for immune checkpoint inhibitors. Cell Rep Med. 2024;5: 101621.","journal-title":"Cell Rep Med"},{"key":"1722_CR132","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","volume":"16","author":"S Sivori","year":"2019","unstructured":"Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC, Moretta L. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol. 2019;16:430\u201341.","journal-title":"Cell Mol Immunol"},{"key":"1722_CR133","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3389\/fimmu.2019.00661","volume":"10","author":"A Frazao","year":"2019","unstructured":"Frazao A, Rethacker L, Messaoudene M, Avril MF, Toubert A, Dulphy N, Caignard A. NKG2D\/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment. Front Immunol. 2019;10:661.","journal-title":"Front Immunol"},{"key":"1722_CR134","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3324\/haematol.2019.242453","volume":"106","author":"M Fayon","year":"2021","unstructured":"Fayon M, Martinez-Cingolani C, Abecassis A, Roders N, Nelson E, Choisy C, Talbot A, Bensussan A, Fermand JP, Arnulf B, Bories JC. Bi38-3 is a novel CD38\/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma. Haematologica. 2021;106:1193\u20137.","journal-title":"Haematologica"},{"key":"1722_CR135","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","volume":"8","author":"E Letouz\u00e9","year":"2024","unstructured":"Letouz\u00e9 E, Moreau P, Munshi N, Samur M, Minvielle S, Touzeau C. Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications. Blood Adv. 2024;8:2952\u20139.","journal-title":"Blood Adv"},{"key":"1722_CR136","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, Leblay N, Maity R, Sankowski R, Lee H, Barakat E, Ahn S, Weinhold N, Rippe K, Bunse L, Platten M, Goldschmidt H, M\u00fcller-Tidow C, Raab MS, Bahlis NJ. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023;41:711-725.e716.","journal-title":"Cancer Cell"},{"key":"1722_CR137","doi-asserted-by":"crossref","unstructured":"A. K. Mishra, A. Gupta, G. Dagar, D. Das, A. Chakraborty, S. Haque, C. P. Prasad, A. Singh, A. A. Bhat, M. A. Macha, M. Benali, K. S. Saini, R. A. Previs, D. Saini, D. Saha, P. Dutta, A. R. Bhatnagar, M. Darswal, A. Shankar, M. Singh, CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond. Vaccines (Basel) 11, (2023).","DOI":"10.3390\/vaccines11111721"},{"key":"1722_CR138","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O\u2019Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"1722_CR139","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1158\/1078-0432.CCR-24-0352","volume":"30","author":"Y Yang","year":"2024","unstructured":"Yang Y, Qin S, Yang M, Wang T, Feng R, Zhang C, Zheng E, Li Q, Xiang P, Ning S, Xu X, Zuo X, Zhang S, Yun X, Zhou X, Wang Y, He L, Shang Y, Sun L, Liu H. Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy. Clin Cancer Res. 2024;30:4201\u201314.","journal-title":"Clin Cancer Res"},{"key":"1722_CR140","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","volume":"27","author":"YC Cohen","year":"2021","unstructured":"Cohen YC, Zada M, Wang SY, Bornstein C, David E, Moshe A, Li B, Shlomi-Loubaton S, Gatt ME, Gur C, Lavi N, Ganzel C, Luttwak E, Chubar E, Rouvio O, Vaxman I, Pasvolsky O, Ballan M, Tadmor T, Nemets A, Jarchowcky-Dolberg O, Shvetz O, Laiba M, Shpilberg O, Dally N, Avivi I, Weiner A, Amit I. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021;27:491\u2013503.","journal-title":"Nat Med"},{"key":"1722_CR141","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1002\/jcp.29494","volume":"235","author":"Z Payandeh","year":"2020","unstructured":"Payandeh Z, Khalili S, Somi MH, Mard-Soltani M, Baghbanzadeh A, Hajiasgharzadeh K, Samadi N, Baradaran B. PD-1\/PD-L1-dependent immune response in colorectal cancer. J Cell Physiol. 2020;235:5461\u201375.","journal-title":"J Cell Physiol"},{"key":"1722_CR142","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.ccell.2024.06.009","volume":"42","author":"Y Chen","year":"2024","unstructured":"Chen Y, Wang D, Li Y, Qi L, Si W, Bo Y, Chen X, Ye Z, Fan H, Liu B, Liu C, Zhang L, Zhang X, Li Z, Zhu L, Wu A, Zhang Z. Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. Cancer Cell. 2024;42:1268-1285.e1267.","journal-title":"Cancer Cell"},{"key":"1722_CR143","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12943-024-02180-y","volume":"23","author":"X Zhou","year":"2024","unstructured":"Zhou X, Han J, Zuo A, Ba Y, Liu S, Xu H, Zhang Y, Weng S, Zhou Z, Liu L, Luo P, Cheng Q, Zhang C, Chen Y, Shan D, Liu B, Yang S, Han X, Deng J, Liu Z. THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K\/AKT activation in colorectal cancer. Mol Cancer. 2024;23:282.","journal-title":"Mol Cancer"},{"key":"1722_CR144","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.4254\/wjh.v13.i9.1132","volume":"13","author":"A Jain","year":"2021","unstructured":"Jain A, Chitturi S, Peters G, Yip D. Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice. World J Hepatol. 2021;13:1132\u201342.","journal-title":"World J Hepatol"},{"key":"1722_CR145","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s43018-023-00672-2","volume":"5","author":"Z Li","year":"2024","unstructured":"Li Z, Pai R, Gupta S, Currenti J, Guo W, Di Bartolomeo A, Feng H, Zhang Z, Li Z, Liu L, Singh A, Bai Y, Yang B, Mishra A, Yang K, Qiao L, Wallace M, Yin Y, Xia Q, Chan JKY, George J, Chow PK, Ginhoux F, Sharma A. Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy. Nat Cancer. 2024;5:167\u201386.","journal-title":"Nat Cancer"},{"key":"1722_CR146","doi-asserted-by":"crossref","unstructured":"Y. Myojin, S. Babaei, R. Trehan, C. Hoffman, N. Kedei, B. Ruf, M. R. Benmebarek, K. C. Bauer, P. Huang, C. Ma, C. Monge, C. Xie, D. Hrones, A. G. Duffy, P. Armstrong, L. Kocheise, F. Desmond, J. Buchalter, M. Galligan, C. Cantwell, R. Ryan, J. McCann, M. Bourke, R. Mac Nicholas, R. McDermott, J. Awosika, M. Cam, R. Krebs, A. Budhu, M. Revsine, W. D. Figg, D. E. Kleiner, B. Redd, B. J. Wood, X. W. Wang, F. Korangy, M. Claassen, T. F. Greten, Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab. Gut, (2025).","DOI":"10.1136\/gutjnl-2024-334026"},{"key":"1722_CR147","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1038\/onc.2014.115","volume":"34","author":"R Ferraldeschi","year":"2015","unstructured":"Ferraldeschi R, Welti J, Luo J, Attard G, de Bono JS. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene. 2015;34:1745\u201357.","journal-title":"Oncogene"},{"key":"1722_CR148","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1126\/science.aab0917","volume":"349","author":"DT Miyamoto","year":"2015","unstructured":"Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J, Arora KS, Desai N, Dahl DM, Sequist LV, Smith MR, Kapur R, Wu CL, Shioda T, Ramaswamy S, Ting DT, Toner M, Maheswaran S, Haber DA. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015;349:1351\u20136.","journal-title":"Science"},{"key":"1722_CR149","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12935-021-02024-5","volume":"21","author":"G Cheng","year":"2021","unstructured":"Cheng G, Dong H, Yang C, Liu Y, Wu Y, Zhu L, Tong X, Wang S. A review on the advances and challenges of immunotherapy for head and neck cancer. Cancer Cell Int. 2021;21:406.","journal-title":"Cancer Cell Int"},{"key":"1722_CR150","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","volume":"12","author":"P Sarantis","year":"2020","unstructured":"Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol. 2020;12:173\u201381.","journal-title":"World J Gastrointest Oncol"},{"key":"1722_CR151","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu ZI, O\u2019Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:7\u201324.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1722_CR152","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2020","unstructured":"Dominguez CX, M\u00fcller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, Breart B, Foreman O, Bainbridge TW, Castiglioni A, Senbabaoglu Y, Modrusan Z, Liang Y, Junttila MR, Klijn C, Bourgon R, Turley SJ. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15(+) Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. Cancer Discov. 2020;10:232\u201353.","journal-title":"Cancer Discov"},{"key":"1722_CR153","doi-asserted-by":"crossref","unstructured":"Y. Abaza, A. M. Zeidan, Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Cells 11, (2022).","DOI":"10.3390\/cells11142249"},{"key":"1722_CR154","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","volume":"10","author":"NJ Short","year":"2020","unstructured":"Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, Daver N. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discov. 2020;10:506\u201325.","journal-title":"Cancer Discov"},{"key":"1722_CR155","doi-asserted-by":"publisher","first-page":"1410638","DOI":"10.3389\/fimmu.2024.1410638","volume":"15","author":"L Ricard","year":"2024","unstructured":"Ricard L, Cervera P, Stocker N, Corre E, Van de Wyngaert Z, Banet A, Marjanovic Z, Dulery R, Bravetti C, Joly AC, Baylatry MT, Coppo P. A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed\/refractory AITL. Front Immunol. 2024;15:1410638.","journal-title":"Front Immunol"},{"key":"1722_CR156","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed\/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label. Phase II Study Cancer Discov. 2019;9:370\u201383.","journal-title":"Phase II Study Cancer Discov"},{"key":"1722_CR157","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/bloodadvances.2021004583","volume":"5","author":"HA Abbas","year":"2021","unstructured":"Abbas HA, Alaniz Z, Mackay S, Cyr M, Zhou J, Issa GC, Alfayez M, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Konopleva M, Andreeff M, Daver N. Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy. Blood Adv. 2021;5:4569\u201374.","journal-title":"Blood Adv"},{"key":"1722_CR158","doi-asserted-by":"publisher","first-page":"1082235","DOI":"10.3389\/fonc.2022.1082235","volume":"12","author":"K Miyao","year":"2022","unstructured":"Miyao K, Yokota H, Sakemura RL. Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma? Front Oncol. 2022;12:1082235.","journal-title":"Front Oncol"},{"key":"1722_CR159","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:31\u201342.","journal-title":"Lancet Oncol"},{"key":"1722_CR160","doi-asserted-by":"crossref","unstructured":"Q. Deng, G. Han, N. Puebla-Osorio, M. C. J. Ma, P. Strati, B. Chasen, E. Dai, M. Dang, N. Jain, H. Yang, Y. Wang, S. Zhang, R. Wang, R. Chen, J. Showell, S. Ghosh, S. Patchva, Q. Zhang, R. Sun, F. Hagemeister, L. Fayad, F. Samaniego, H. C. Lee, L. J. Nastoupil, N. Fowler, R. Eric Davis, J. Westin, S. S. Neelapu, L. Wang, M. R. Green, Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26, 1878\u20131887 (2020).","DOI":"10.1038\/s41591-020-1061-7"},{"key":"1722_CR161","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.tips.2024.04.006","volume":"45","author":"JM Konen","year":"2024","unstructured":"Konen JM, Wu H, Gibbons DL. Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities. Trends Pharmacol Sci. 2024;45:520\u201336.","journal-title":"Trends Pharmacol Sci"},{"key":"1722_CR162","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41421-024-00703-x","volume":"10","author":"Y Jin","year":"2024","unstructured":"Jin Y, Wu Y, Reuben A, Zhu L, Gay CM, Wu Q, Zhou X, Mo H, Zheng Q, Ren J, Fang Z, Peng T, Wang N, Ma L, Fan Y, Song H, Zhang J, Chen M. Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer. Cell Discov. 2024;10:93.","journal-title":"Cell Discov"},{"key":"1722_CR163","doi-asserted-by":"crossref","unstructured":"H. Chen, C. Deng, J. Gao, J. Wang, F. Fu, Y. Wang, Q. Wang, M. Zhang, S. Zhang, F. Fan, K. Liu, B. Yang, Q. He, Q. Zheng, X. Shen, J. Wang, T. Hu, C. Zhu, F. Yang, Y. He, H. Hu, J. Wang, Y. Li, Y. Zhang, Z. Cao, Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer. Cancer Cell, (2025).","DOI":"10.2139\/ssrn.4909422"},{"key":"1722_CR164","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-21-4383","volume":"28","author":"J Wang","year":"2022","unstructured":"Wang J, Kunzke T, Prade VM, Shen J, Buck A, Feuchtinger A, Haffner I, Luber B, Liu DHW, Langer R, Lordick F, Sun N, Walch A. Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients. Clin Cancer Res. 2022;28:2865\u201377.","journal-title":"Clin Cancer Res"},{"key":"1722_CR165","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, Todd KL, Henderson MA, Giuffrida L, Petley EV, Sek K, Mardiana S, Gide TN, Quek C, Scolyer RA, Long GV, Wilmott JS, Loi S, Darcy PK, Beavis PA. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clin Cancer Res. 2020;26:487\u2013504.","journal-title":"Clin Cancer Res"},{"key":"1722_CR166","doi-asserted-by":"crossref","unstructured":"R. Reschke, T. F. Gajewski, CXCL9 and CXCL10 bring the heat to tumors. Sci Immunol 7, eabq6509 (2022).","DOI":"10.1126\/sciimmunol.abq6509"},{"key":"1722_CR167","doi-asserted-by":"crossref","unstructured":"T. Hoch, D. Schulz, N. Eling, J. M. G\u00f3mez, M. P. Levesque, B. Bodenmiller, Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy. Sci Immunol 7, eabk1692 (2022).","DOI":"10.1126\/sciimmunol.abk1692"},{"key":"1722_CR168","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, McNamara KL, Granja JM, Sarin KY, Brown RA, Gupta RK, Curtis C, Bucktrout SL, Davis MM, Chang ALS, Chang HY. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019;25:1251\u20139.","journal-title":"Nat Med"},{"key":"1722_CR169","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/d41573-022-00030-4","volume":"21","author":"S Upadhaya","year":"2022","unstructured":"Upadhaya S, Neftelinov ST, Hodge J, Campbell J. Challenges and opportunities in the PD1\/PDL1 inhibitor clinical trial landscape. Nat Rev Drug Discov. 2022;21:482\u20133.","journal-title":"Nat Rev Drug Discov"},{"key":"1722_CR170","doi-asserted-by":"crossref","unstructured":"T. D. Wu, S. Madireddi, P. E. de Almeida, R. Banchereau, Y. J. Chen, A. S. Chitre, E. Y. Chiang, H. Iftikhar, W. E. O'Gorman, A. Au-Yeung, C. Takahashi, L. D. Goldstein, C. Poon, S. Keerthivasan, D. E. de Almeida Nagata, X. Du, H. M. Lee, K. L. Banta, S. Mariathasan, M. Das Thakur, M. A. Huseni, M. Ballinger, I. Estay, P. Caplazi, Z. Modrusan, L. Delamarre, I. Mellman, R. Bourgon, J. L. Grogan, Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274\u2013278 (2020).","DOI":"10.1038\/s41586-020-2056-8"},{"key":"1722_CR171","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s43018-022-00433-7","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu B, Zhang Y, Wang D, Hu X, Zhang Z. Single-cell meta-analyses reveal responses of tumor-reactive CXCL13(+) T cells to immune-checkpoint blockade. Nat Cancer. 2022;3:1123\u201336.","journal-title":"Nat Cancer"},{"key":"1722_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2024.100659","volume":"4","author":"C Cao","year":"2024","unstructured":"Cao C, Xu M, Wei Y, Peng T, Lin S, Liu X, Xu Y, Chu T, Liu S, Wu P, Hu B, Ding W, Li L, Ma D, Wu P. CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8(+) T cells via JAK2\/STAT3 pathway. Cell Genom. 2024;4: 100659.","journal-title":"Cell Genom"},{"key":"1722_CR173","doi-asserted-by":"crossref","unstructured":"D. Bressan, G. Battistoni, G. J. Hannon, The dawn of spatial omics. Science 381, eabq4964 (2023).","DOI":"10.1126\/science.abq4964"},{"key":"1722_CR174","doi-asserted-by":"crossref","unstructured":"J. Wang, F. Ye, H. Chai, Y. Jiang, T. Wang, X. Ran, Q. Xia, Z. Xu, Y. Fu, G. Zhang, H. Wu, G. Guo, H. Guo, Y. Ruan, Y. Wang, D. Xing, X. Xu, Z. Zhang, Advances and applications in single-cell and spatial genomics. Sci China Life Sci, (2024).","DOI":"10.1007\/s11427-024-2770-x"},{"key":"1722_CR175","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/s41467-020-14482-y","volume":"11","author":"MJ Zhang","year":"2020","unstructured":"Zhang MJ, Ntranos V, Tse D. Determining sequencing depth in a single-cell RNA-seq experiment. Nat Commun. 2020;11:774.","journal-title":"Nat Commun"},{"key":"1722_CR176","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.tibtech.2020.02.013","volume":"38","author":"A Ma","year":"2020","unstructured":"Ma A, McDermaid A, Xu J, Chang Y, Ma Q. Integrative Methods and Practical Challenges for Single-Cell Multi-omics. Trends Biotechnol. 2020;38:1007\u201322.","journal-title":"Trends Biotechnol"},{"key":"1722_CR177","doi-asserted-by":"crossref","unstructured":"D. L\u00e4hnemann, J. K\u00f6ster, E. Szczurek, D. J. McCarthy, S. C. Hicks, M. D. Robinson, C. A. Vallejos, K. R. Campbell, N. Beerenwinkel, A. Mahfouz, L. Pinello, P. Skums, A. Stamatakis, C. S. Attolini, S. Aparicio, J. Baaijens, M. Balvert, B. Barbanson, A. Cappuccio, G. Corleone, B. E. Dutilh, M. Florescu, V. Guryev, R. Holmer, K. Jahn, T. J. Lobo, E. M. Keizer, I. Khatri, S. M. Kielbasa, J. O. Korbel, A. M. Kozlov, T. H. Kuo, B. P. F. Lelieveldt, Mandoiu, II, J. C. Marioni, T. Marschall, F. M\u00f6lder, A. Niknejad, A. R\u0105czkowska, M. Reinders, J. Ridder, A. E. Saliba, A. Somarakis, O. Stegle, F. J. Theis, H. Yang, A. Zelikovsky, A. C. McHardy, B. J. Raphael, S. P. Shah, A. Sch\u00f6nhuth, Eleven grand challenges in single-cell data science. Genome Biol 21, 31 (2020).","DOI":"10.1186\/s13059-020-1926-6"},{"key":"1722_CR178","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-024-01596-9","volume":"17","author":"X Liu","year":"2024","unstructured":"Liu X, Peng T, Xu M, Lin S, Hu B, Chu T, Liu B, Xu Y, Ding W, Li L, Cao C, Wu P. Spatial multi-omics: deciphering technological landscape of integration of multi-omics and its applications. J Hematol Oncol. 2024;17:72.","journal-title":"J Hematol Oncol"},{"key":"1722_CR179","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41592-023-02139-9","volume":"21","author":"K Zhang","year":"2024","unstructured":"Zhang K, Zemke NR, Armand EJ, Ren B. A fast, scalable and versatile tool for analysis of single-cell omics data. Nat Methods. 2024;21:217\u201327.","journal-title":"Nat Methods"},{"key":"1722_CR180","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrd.2015.16","volume":"15","author":"JR Heath","year":"2016","unstructured":"Heath JR, Ribas A, Mischel PS. Single-cell analysis tools for drug discovery and development. Nat Rev Drug Discov. 2016;15:204\u201316.","journal-title":"Nat Rev Drug Discov"},{"key":"1722_CR181","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.1016\/j.cell.2024.09.012","volume":"187","author":"CR Walker","year":"2024","unstructured":"Walker CR, Li X, Chakravarthy M, Lounsbery-Scaife W, Choi YA, Singh R, G\u00fcrsoy G. Private information leakage from single-cell count matrices. Cell. 2024;187:6537-6549.e6510.","journal-title":"Cell"},{"key":"1722_CR182","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/iub.2888","volume":"76","author":"M Ebrahimnezhad","year":"2024","unstructured":"Ebrahimnezhad M, Asl SH, Rezaie M, Molavand M, Yousefi B, Majidinia M. lncRNAs: New players of cancer drug resistance via targeting ABC transporters. IUBMB Life. 2024;76:883\u2013921.","journal-title":"IUBMB Life"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01722-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01722-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01722-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:03:36Z","timestamp":1751447016000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01722-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":182,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1722"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01722-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}